Clinical trials: NSCLC, Stage I
Non-small-cell Lung Cancer
A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer
This is a Phase I-II study designed to investigate nimotuzumab (TheraCIM h-R3) in combination with external radiation in patients with non-small cell lung cancer.
- Trial name
- NCT00369447
- Testing
- External radiotherapy, nimotuzumab
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 52 people
- Sponsor
- YM BioSciences
NSCLC
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients
The purpose of this study is to determine if the combination of Taxotere and exisulind is an effective and safe treatment for patients with advanced NSCLC who have failed a prior platinum-containing regimen.
- Trial name
- NCT00072618
- Testing
- Exisulind
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Cancer, Solid Tumor
ACTolog in Patients With Solid Cancers
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
- Trial name
- ACTolog (NCT02876510)
- Testing
- Fludarabine, Cyclophosphamide, IMA101 product
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Immatics US, Inc.
Ovarian Cancer, Endometrial Cancer
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
This is a data collection study, also referred to as a "screening" study; no investigational or standard therapy will be administered as part of this study.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Colo-rectal Cancer, Cholangiocarcinoma
- Trial name
- NCT05124743
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Alaunos Therapeutics
Non-Small-Cell Lung Carcinoma
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
This open-label, non-randomized, multicenter, Phase 1/2 study will evaluate the safety and efficacy of alectinib in participants with non-small cell lung cancer who have ALK mutation and failed crizotinib treatment.
- Trial name
- NCT01801111
- Testing
- Erlotinib, Alectinib
- Where
- 84 sites in United States, Australia and 14 more
- Volunteers
- 138 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Non-Small Cell
Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery
The purpose of this clinical study is to assess the safety and immunogenicity of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery.
- Trial name
- NCT01159964
- Testing
- Immunotherapeutic GSK2302032A, different formulations
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics
To study the pharmacokinetic characteristics of TQ-B3456 in the human body, recommend a reasonable regimen for subsequent research.
- Trial name
- NCT03754244
- Testing
- TQB3456
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
To determine the appropriateness of the dose of nintedanib 200 mg b.i.d. plus docetaxel 75 mg/m2 as starting dose by evaluating the safety in Japanese patients with body surface area (BSA) <1.5 m2 and locally advanced or…
- Trial name
- NCT02300298
- Testing
- Nintedanib, Docetaxel
- Where
- 6 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung Cancer
The study objective is to evaluate the maximum tolerated dose, safety and efficacy of patupilone in patients with NSCLC who have progressed after prior chemotherapy.
- Trial name
- NCT00171834
- Testing
- Patupilone
- Where
- 4 sites in United States
- Volunteers
- 89 people
- Sponsor
- Novartis Pharmaceuticals
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China
This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg/5 µCi dose of…
- Trial name
- NCT07620951
- Testing
- [14C]Zorifertinib Oral Formulation
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Neoplasms
BAY1238097, First in Man
This is the first study where BAY1238097 is given to humans. Impact of the study is to evaluate if patients with advanced cancer show clinical benefit under the treatment with BET(Bromodomain and extraterminal domain family )…
- Trial name
- NCT02369029
- Testing
- BAY 1238097
- Where
- 6 sites in United States, Finland and 4 more
- Volunteers
- 8 people
- Sponsor
- Bayer
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with…
- Conditions
- Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
- Trial name
- NCT02912949
- Testing
- zenocutuzumab (MCLA-128)
- Where
- 64 sites in United States, Austria and 16 more
- Volunteers
- 250 people
- Sponsor
- Partner Therapeutics, Inc.
Non-small Cell Lung Cancer
A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)
This is a phase I, open-label, dose-escalation trial of TG6050 administered by single or repeated IV infusion(s).
- Trial name
- NCT05788926
- Testing
- TG6050
- Where
- 5 sites in France
- Volunteers
- 22 people
- Sponsor
- Transgene
Non-small Cell Lung Cancer, Colorectal Cancer
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
QLC1101 is a selective reversible inhibitor of KRAS G12D, with the dosage form of capsules and administration route of oral administration.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT06403735
- Testing
- QLC1101
- Where
- 5 sites in China
- Volunteers
- 250 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer, EGFR Sensitive Mutation
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
This multicenter, randomized, controlled, double-blind, double-simulated, Phase III study is designed to evaluate the efficacy and safety of Befotertinib compared with Icotinib as adjuvant treatment in EGFR-sensitive…
- Conditions
- Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
- Trial name
- NCT06041776
- Where
- 3 sites in China
- Volunteers
- 570 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
NSCLC
To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects
To evaluate the safety and tolerability of food to Alkotinib Capsules in healthy subjects
- Trial name
- NCT04032821
- Testing
- Alkotinib（300mg)
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
This is an open-label, multicenter Phase Ib/II clinical study evaluating GFH276 in combination with tislelizumab plus pemetrexed/platinum based regimen as first-line therapy in participants with locally advanced or metastatic…
- Trial name
- GFH276X1203 (NCT07846358)
- Testing
- GFH276, with or without Tislelizumab, Pemetrexed
- Volunteers
- 84 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Non-small Cell Lung Cancer (NSCLC)
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safety profile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK) exposure and pharmacodynamic (PD) properties as well as…
- Trial name
- STX-241 FIH (NCT06567015)
- Testing
- STX-241
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 171 people
- Sponsor
- Pierre Fabre Medicament
NSCLC
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
This is a consolidation therapy trial evaluating GI-4000 in subjects with NSCLC treated with curative intent who are disease free at their first post-treatment restaging assessment.
- Trial name
- NCT00655161
- Testing
- GI-4000
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- GlobeImmune
Non-Small Cell Lung Cancer
Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC
This is an open-label, dose-escalation Phase I study to evaluate the safety and tolerability of RX001 monotherapy in patients with advanced KRAS mutant NSCLC.
- Trial name
- NCT06934590
- Testing
- RX001
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- GeneCraft Inc.